MedAvail (MDVLQ) 10-Q 10 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 08, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-36533
Entity Registrant Name	MEDAVAIL HOLDINGS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	90-0772394
Entity Address, Address Line One	4720 East Cotton Gin Loop,
Entity Address, Address Line Two	Suite 220,
Entity Address, City or Town	Phoenix,
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85040
City Area Code	905
Local Phone Number	812-0023
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	MDVL
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		80,045,696
Entity Central Index Key	0001402479
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 27,196	$ 19,689
Restricted cash	676	400
Accounts receivable (net of allowance for doubtful accounts of $186 thousand for September 30, 2022, $66 thousand for December 31, 2021)	2,262	1,189
Inventories	6,401	3,916
Prepaid expenses and other current assets	2,863	2,191
Total current assets	39,398	27,385
Property, plant and equipment, net	6,370	5,692
Intangible assets, net	1,580	2,300
Right-of-use assets	2,270	2,538
Other assets	233	228
Total assets	49,851	38,143
Current liabilities:
Accounts payable	2,006	2,477
Accrued liabilities	1,383	1,530
Accrued payroll and benefits	2,869	2,733
Deferred revenue	70	83
Current portion of lease obligations	728	682
Total current liabilities	7,056	7,505
Long-term debt, net	9,751	9,538
Long-term portion of lease obligations	1,738	2,027
Total liabilities	18,545	19,070
Commitments and contingencies
Stockholders' equity:
Common shares ($0.001 par value, 300,000,000 shares authorized, 80,045,696 and 32,902,048 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively)	80	33
Warrants	11,148	1,373
Additional paid-in-capital	255,642	216,685
Accumulated other comprehensive loss	(6,928)	(6,928)
Accumulated deficit	(228,636)	(192,090)
Total stockholders' equity	31,306	19,073
Total liabilities and stockholders' equity	$ 49,851	$ 38,143

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 186	$ 66
Common shares, par value (in USD per share)	$ 0.001	$ 0.001
Common shares, authorized (in shares)	300,000,000	300,000,000
Common shares, issued (in shares)	80,045,696	32,902,048
Common shares, outstanding (in shares)	80,045,696	32,902,048

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Total revenue	$ 11,461	$ 5,792	$ 31,759	$ 14,849
Cost of products sold and services:
Total cost of products sold and services	10,169	5,606	29,048	14,170
Operating expense:
Pharmacy operations	4,392	3,750	11,970	9,428
General and administrative	6,087	5,320	18,729	16,733
Selling and marketing	2,126	1,909	6,738	5,056
Research and development	178	232	952	601
Total operating expense	12,783	11,211	38,389	31,818
Operating loss	(11,491)	(11,025)	(35,678)	(31,139)
Other gain (loss), net	0	7	0	206
Interest income	0	7	1	74
Interest expense	(315)	(260)	(845)	(328)
Loss before income taxes	(11,806)	(11,271)	(36,522)	(31,187)
Income tax expense	0	(2)	(24)	(2)
Net loss	(11,806)	(11,273)	(36,546)	(31,189)
Comprehensive loss	$ (11,806)	$ (11,273)	$ (36,546)	$ (31,189)
Net loss per share - basic (in USD per share)	$ (0.15)	$ (0.34)	$ (0.60)	$ (0.96)
Net loss per share - diluted (in USD per share)	$ (0.15)	$ (0.34)	$ (0.60)	$ (0.96)
Weighted average shares outstanding - basic (in shares)	80,045,995	32,750,831	60,947,511	32,580,199
Weighted average shares outstanding - diluted (in shares)	80,045,995	32,750,831	60,947,511	32,580,199
Pharmacy and hardware revenue
Revenue:
Total revenue	$ 11,266	$ 5,659	$ 31,210	$ 14,165
Cost of products sold and services:
Total cost of products sold and services	10,113	5,539	28,827	13,744
Service revenue
Revenue:
Total revenue	195	133	549	684
Cost of products sold and services:
Total cost of products sold and services	$ 56	$ 67	$ 221	$ 426

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands		Total	Common Shares	Preferred Shares		Warrants	Additional Paid-in-Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Common Stock, Balance at beginning of period (in shares) at Dec. 31, 2020			31,816,020
Balance at beginning of period at Dec. 31, 2020		$ 61,067	$ 32	$ 0	[1]	$ 2,614	$ 213,624	$ (148,275)	$ (6,928)
Preferred Stock, Balance at beginning of period (in shares) at Dec. 31, 2020	[1]			0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(31,189)						(31,189)
Exercise of options (in shares)			144,101
Exercise of options		241					241
Exercise of warrants (in shares)			794,804
Exercise of warrants		151	$ 1			(1,241)	1,391
Share-based compensation		948					948
Common Stock, Balance at end of period (in shares) at Sep. 30, 2021			32,754,925
Balance at end of period at Sep. 30, 2021		31,218	$ 33	$ 0	[1]	1,373	216,204	(179,464)	(6,928)
Preferred Stock, Balance at end of period (in shares) at Sep. 30, 2021	[1]			0
Common Stock, Balance at beginning of period (in shares) at Jun. 30, 2021			32,583,734
Balance at beginning of period at Jun. 30, 2021		42,099	$ 33	$ 0	[1]	1,485	215,700	(168,191)	(6,928)
Preferred Stock, Balance at beginning of period (in shares) at Jun. 30, 2021	[1]			0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(11,273)						(11,273)
Exercise of warrants (in shares)			171,191
Exercise of warrants		27				(112)	139
Share-based compensation		365					365
Common Stock, Balance at end of period (in shares) at Sep. 30, 2021			32,754,925
Balance at end of period at Sep. 30, 2021		$ 31,218	$ 33	$ 0	[1]	1,373	216,204	(179,464)	(6,928)
Preferred Stock, Balance at end of period (in shares) at Sep. 30, 2021	[1]			0
Common Stock, Balance at beginning of period (in shares) at Dec. 31, 2021		32,902,048	32,902,048
Balance at beginning of period at Dec. 31, 2021		$ 19,073	$ 33	$ 0	[1]	1,373	216,685	(192,090)	(6,928)
Preferred Stock, Balance at beginning of period (in shares) at Dec. 31, 2021	[1]			0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(36,546)						(36,546)
Issuance of common shares (in shares)			47,058,820
Issuance of common shares		46,961	$ 47				46,914
Issuance of warrants		$ 0				9,775	(9,775)
Shares issued for vested RSUs (in shares)			30,833
Exercise of options (in shares)		0
Exercise of warrants (in shares)		0
Issuance of common shares under employee stock purchase plan (in shares)			53,995
Issuance of common shares under employee stock purchase plan		$ 77					77
Share-based compensation		$ 1,741					1,741
Common Stock, Balance at end of period (in shares) at Sep. 30, 2022		80,045,696	80,045,696
Balance at end of period at Sep. 30, 2022		$ 31,306	$ 80	$ 0	[1]	11,148	255,642	(228,636)	(6,928)
Preferred Stock, Balance at end of period (in shares) at Sep. 30, 2022	[1]			0
Common Stock, Balance at beginning of period (in shares) at Jun. 30, 2022			70,609,972
Balance at beginning of period at Jun. 30, 2022		32,787	$ 71	$ 0	[1]	8,876	247,598	(216,830)	(6,928)
Preferred Stock, Balance at beginning of period (in shares) at Jun. 30, 2022	[1]			0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(11,806)						(11,806)
Issuance of common shares (in shares)			9,411,765
Issuance of common shares		9,760	$ 9				9,751
Issuance of warrants		0				2,272	(2,272)
Shares issued for vested RSUs (in shares)			23,959
Share-based compensation		$ 565					565
Common Stock, Balance at end of period (in shares) at Sep. 30, 2022		80,045,696	80,045,696
Balance at end of period at Sep. 30, 2022		$ 31,306	$ 80	$ 0	[1]	$ 11,148	$ 255,642	$ (228,636)	$ (6,928)
Preferred Stock, Balance at end of period (in shares) at Sep. 30, 2022	[1]			0
[1]$0.001 par value, 10,000,000 shares authorized for all periods presented.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Stockholders' Equity [Abstract]
Preferred shares, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred shares, authorized (in shares)	10,000,000	10,000,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (11,806)	$ (11,273)	$ (36,546)	$ (31,189)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant, and equipment	300	300	891	928
Amortization of intangible and leased assets			2,141	877
Bad debt and other non-cash receivables adjustments			120	47
Term loan discount amortization and interest accretion on debt			213	0
Impairment of lease asset			(27)	0
Share-based compensation expense	565	365	1,741	948
PPP loan forgiveness gain			0	(161)
Changes in operating assets and liabilities:
Accounts receivable			(1,193)	398
Inventory			(3,354)	(2,511)
Prepaid expenses and other current assets			(672)	772
Accounts payable, accrued expenses and other liabilities			(137)	2,180
Deferred revenue			(13)	42
Operating lease liability due to cash payments			(447)	(505)
Net cash used in operating activities			(37,283)	(28,174)
Cash flows from investing activities:
Purchase of property, plant and equipment			(804)	(680)
Payment of security deposits			(5)	(45)
Purchase of intangible and other assets			(1,088)	(1,544)
Net cash used in investing activities			(1,897)	(2,269)
Cash flows from financing activities:
Proceeds from issuance of common shares, net			46,961	0
Proceeds from issuance of common shares upon exercise of options and warrants			0	392
Proceeds from issuance of common shares upon exercise of employee stock purchase plan			77	0
Proceeds from debt			0	10,000
Payment of debt issuance costs			0	(624)
Repayment of debt			0	(1,000)
Payments on finance lease obligations			(75)	(46)
Net cash provided by financing activities			46,963	8,722
Net increase (decrease) in cash, cash equivalents and restricted cash			7,783	(21,721)
Cash, cash equivalents and restricted cash at beginning of period			20,089	57,996	$ 57,996
Cash, cash equivalents and restricted cash at end of period	$ 27,872	$ 36,275	27,872	36,275	$ 20,089
Supplemental cash flow information:
Cash paid for interest			603	125
Supplemental noncash investing and financing activities:
Inventory transferred to property, plant and equipment			869	1,075
Property, plant and equipment transferred to intangible assets			0	46
Purchase of property, plant and equipment in accounts payable			21	56
Purchase of intangible assets in accounts payable			0	398
Fair value of warrants issued upon closing of private placement			9,775	0
Lease liabilities arising from obtaining right of use assets:
Operating leases			206	2,177
Finance leases			$ 73	$ 97

NATURE OF OPERATIONS

NATURE OF OPERATIONS	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NATURE OF OPERATIONSMedAvail Holdings, Inc., or MedAvail, or the Company, a Delaware corporation formerly known as MYOS RENS Technology, is a pharmacy technology and services company that has developed and commercialized an innovative self-service pharmacy, mobile application, and kiosk. The Company’s principal technology and product is the MedCenter, a pharmacist controlled, customer-interactive, prescription dispensing system akin to a “pharmacy in a box” or prescription-dispensing ATM. The MedCenter facilitates live pharmacist counseling via two-way audio-video communication with the ability to dispense prescription medicines under pharmacist control. The Company also operates SpotRx, or the Pharmacy, a full-service retail pharmacy utilizing the Company’s automated pharmacy technology.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	GOING CONCERN Relevant accounting standards require that management make a determination as to whether or not substantial doubt exists as to the Company's ability to continue as a going concern. If substantial doubt does exist, then management should determine if there are plans in place which alleviate that doubt. Since inception through September 30, 2022, the Company has continually incurred losses from operations which have been financed primarily by net cash proceeds from the sale of stock from private placements, the sale of redeemable preferred stock and debt. Net cash used in operating activities for nine months ended September 30, 2022 and 2021 was $37.3 million and $28.2 million, respectively. As of September 30, 2022, the Company had $27.2 million in cash and cash equivalents and an accumulated deficit of $228.6 million. In April 2022, the Company completed a private placement, pursuant to which the Company received $40.0 million in gross proceeds, with an additional $10.0 million in gross proceeds received upon the second close that occurred on July 1, 2022, before deducting placement agent commissions and other offering expenses totaling $3.0 million. Additionally, the private placement included warrants, some of which may be callable at the Company’s option beginning on each of the 12 month and 24 month anniversaries of the warrant issuance dates and subject to the satisfaction of certain pricing conditions relating to the trading of the Company’s shares. See Note 11 for further information regarding the private placement warrants. Due to the Company’s significant and ongoing cash requirements to fund operations, management determined that there is substantial doubt as to the Company’s ability to continue as a going concern. The Company added liquidity resources in 2021 through a senior secured term loan facility with Silicon Valley Bank as described in Note 8, pursuant to which the Company borrowed $10.0 million in aggregate initial term loans. Additionally, as referenced above, the Company raised $40.0 million and $10.0 million in gross proceeds through a private placement that closed in April 2022 and July 2022, respectively. There can be no assurance that the steps management is taking will be successful. If the Company is unable to raise additional capital in sufficient amounts or on acceptable terms, the Company may have to significantly reduce operations or delay, scale back or discontinue development and expansion plans. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s ultimate success will largely depend on continued development and deployment of MedCenter kiosks and SpotRx pharmacy operations and the ability to raise significant additional funding.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements as of September 30, 2022 and for the three and nine months ended September 30, 2022 and 2021 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information and in accordance with the rules of the Securities and Exchange Commission ("SEC") applicable to interim reports of companies filing as a smaller reporting company. Accordingly, the unaudited interim condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The condensed consolidated balance sheet as of December 31, 2021 was derived from the Company's audited consolidated financial statements but does not include all disclosures required by GAAP for audited financial statements. In the opinion of the Company's management, the interim information includes all adjustments, which include normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, 2021 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission, or SEC on March 29, 2022, or the 2021 Form 10-K. The preparation of financial statements in accordance with US GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. Estimates are used in accounting for, among other things, revenue recognition, contract loss accruals, excess, slow-moving and obsolete inventories, product warranty accruals, loss accruals on service agreements, share-based compensation expense, allowance for doubtful accounts, depreciation and amortization and in-process research and development intangible assets, and impairment of long-lived assets and contingencies. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the condensed consolidated financial statements in the period they are deemed to be necessary. Risks and uncertainties relating to COVID-19 The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID-19. The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors, including but not limited to, the severity and duration of COVID-19, the extent to which it will impact the Company's clinic customers, employees, suppliers, vendors, and business partners. The Company assessed certain accounting matters that require consideration of estimates and assumptions in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of September 30, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s recoverability of, intangible and other long-lived assets including operating lease right-of-use assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s condensed consolidated financial statements in future reporting periods. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results could differ from these estimates and any such differences may be material to the Company’s financial statements. Principles of consolidation The unaudited condensed consolidated financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated. Reclassifications During the fourth quarter of 2021, management reclassified certain operating expenses to reflect the costs attributable to pharmacy operations. Specifically, certain costs were reclassified from general and administrative expenses, to pharmacy operations expenses and selling and marketing expenses. This reclassification had no impact on the operating loss subtotal within the consolidated statements of operations and comprehensive loss. The effect of the reclassifications within the condensed consolidated statement of operations and comprehensive loss for 2021 are as follows (in thousands): Three Months Ended September 30, 2021 Current presentation As previously reported Change Pharmacy operations $ 3,750 $ 2,395 $ 1,355 General and administrative 5,320 6,805 (1,485) Selling and marketing 1,909 1,779 130 $ 10,979 $ 10,979 $ — Nine Months Ended September 30, 2021 Current presentation As previously reported Change Pharmacy operations $ 9,428 $ 6,619 $ 2,809 General and administrative 16,733 19,941 (3,208) Selling and marketing 5,056 4,657 399 $ 31,217 $ 31,217 $ —

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS Measurement of Credit Losses on Financial Statements In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)”- Measurement of Credit Losses on Financial Instruments”, (“ASU 2016-13”), supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, (“ASU 2018-19”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, all other public business entities and private companies, with early adoption permitted. ASU No. 2016-13 will be effective beginning in the first quarter of the Company's fiscal year 2023. The Company is currently evaluating the impact that this new guidance will have on its consolidated financial statements and related disclosures. In June 2022, the FASB issued ASU No. 2022-03, “Fair Value Measurement (Topic 820)”- Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, (“ASU 2022-03”). The amendments in this update clarify the guidance in Topic 820. ASU 2022-03 becomes effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. ASU No. 2022-03 will be effective beginning in the first quarter of the Company's fiscal year 2024. The Company has not yet completed its evaluation of the impact of this new guidance on its consolidated financial statements. Recently Adopted Accounting Standards There was no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s condensed consolidated financial statements through the reporting date.

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	EARNINGS (LOSS) PER SHARE Basic earnings (loss) per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares plus the effect of dilutive potential common shares outstanding during the period. The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price, during the period from the date of issuance to the exercise date. After these warrants were exercised the related issued and outstanding common shares are included in weighted average shares outstanding: Shares Issuance Date Exercise Date 118,228 May 9, 2018 May 10, 2021 309,698 February 11, 2020 May 10, 2021 84,911 June 29, 2020 May 10, 2021 39,208 November 18, 2020 May 10, 2021 19,310 November 18, 2020 Outstanding

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Assets and liabilities measured at fair value on a recurring basis were as follows: Fair Value Hierarchy (in thousands) September 30, 2022 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 27,196 $ 27,196 $ — $ — Restricted cash 676 676 — — Total assets $ 27,872 $ 27,872 $ — $ — Fair Value Hierarchy (in thousands) December 31, 2021 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 19,689 $ 19,689 $ — $ — Restricted cash 400 400 — — Total assets $ 20,089 $ 20,089 $ — $ — The carrying amount of the Company's term loan approximates fair value based upon market interest rates available to us for debt of similar risk and maturities. Refer to Note 8, Debt, for further information.

BALANCE SHEET AND OTHER INFORMA

BALANCE SHEET AND OTHER INFORMATION	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BALANCE SHEET AND OTHER INFORMATION	BALANCE SHEET AND OTHER INFORMATION Restricted cash The Company considers cash to be restricted when withdrawal or general use is legally restricted. During the nine months ended September 30, 2022, the Company recovered the $0.1 million restricted cash balance outstanding at December 31, 2021, that was held as a guarantee for certain purchasing cards. During the same period, pursuant to a Loan and Security Agreement with Silicon Valley Bank dated June 7, 2021 (see Note 8), the Company issued letters of credit to secure certain operating leases, and the Company is required to maintain a $0.7 million balance with the bank to secure the outstanding letters of credit, of which $0.3 million was issued in February 2022. Due to the nature of the deposit, the balance is classified as restricted cash. Restricted cash is included in the balance for cash, cash equivalents and restricted cash presented in the statements of cash flows. Inventory The following table presents detail of inventory balances: September 30, December 31, (in thousands) 2022 2021 Inventory: MedCenter hardware $ 2,464 $ 1,201 Pharmaceuticals 3,275 2,150 Spare parts 662 565 Total inventory $ 6,401 $ 3,916 Pharmaceutical inventory was recognized in pharmacy and hardware cost of products sold at $9.3 million and $5.0 million during the three months ended September 30, 2022 and 2021, respectively, and $26.4 million and $12.2 million during the nine months ended September 30, 2022 and 2021, respectively. MedCenter hardware was recognized in pharmacy and hardware cost of products sold at $0.01 million and $0.1 million during the three months ended September 30, 2022 and 2021, respectively, and $0.2 million and $0.5 million during the nine months ended September 30, 2022 and 2021, respectively. Prepaid expenses and other current assets The following table presents prepaid expenses and other current assets balances: September 30, December 31, (in thousands) 2022 2021 Prepaid expenses and other current assets: Prepaid MedCenter inventory $ 2,204 $ 1,050 Prepaid insurance 292 509 Other 367 632 Total prepaid expenses and other current assets $ 2,863 $ 2,191 Property, plant and equipment, net The following table presents property, plant and equipment balances: Estimated useful lives September 30, December 31, (in thousands) 2022 2021 Property, plant and equipment: MedCenter equipment 8 years $ 7,525 $ 5,875 IT equipment 1 - 3 years 2,390 2,361 Leasehold improvements lesser of useful life or term of lease 980 880 General plant and equipment 5 - 8 years 619 603 Office furniture and equipment 5 - 8 years 538 394 Vehicles 5 years 54 54 Construction-in-process 481 1,021 Total historical cost 12,587 11,188 Accumulated depreciation (6,217) (5,496) Total property, plant and equipment, net $ 6,370 $ 5,692 Depreciation expense of property and equipment was $0.3 million and $0.3 million for the three months ended September 30, 2022 and 2021, respectively, and $0.9 million and $0.9 million for the nine months ended September 30, 2022 and 2021, respectively. Depreciation expense included in pharmacy and hardware cost of products sold was $0.03 million and $0.05 million for the three months ended September 30, 2022 and 2021, respectively, and $0.1 million and $0.1 million for the nine months ended September 30, 2022, and 2021, respectively. Intangible assets, net The following table presents intangible asset balances: September 30, December 31, (in thousands) 2022 2021 Gross intangible assets: Intellectual property $ 3,857 $ 3,857 Software 5,321 4,475 Website and mobile application 583 583 Total intangible assets 9,761 8,915 Accumulated amortization: Intellectual property (3,857) (3,857) Software (3,741) (2,175) Website and mobile application (583) (583) Total accumulated amortization (8,181) (6,615) Total intangible assets, net $ 1,580 $ 2,300 No intangible assets were purchased for the three months ended September 30, 2022. The Company purchased $0.7 million of intangible assets for the three months ended September 30, 2021, and $0.9 million and $1.9 million for the nine months ended September 30, 2022 and 2021, respectively. Amortization expense of intangible assets was $1.3 million and $0.1 million for the three months ended September 30, 2022 and 2021, respectively, and $1.6 million and $0.2 million for the nine months ended September 30, 2022 and 2021, respectively, and are included in operating expenses. The Company’s management team is evaluating its existing systems and software. If management were to determine that certain systems or software were to be replaced in order to achieve greater efficiencies, cost savings, or both, the estimated remaining useful life of some IT equipment and intangible assets may be reduced, resulting in higher depreciation and amortization expense, respectively. Lessee leases Balance sheet amounts for lease assets and leases liabilities are as follows: September 30, December 31, (in thousands) 2022 2021 Assets: Operating $ 2,110 $ 2,376 Finance 160 162 Total assets $ 2,270 $ 2,538 Liabilities: Operating: Current $ 632 $ 599 Long-term 1,673 1,947 Finance: Current 96 83 Long-term 65 80 Total liabilities $ 2,466 $ 2,709 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows: September 30, December 31, (in thousands) 2022 2021 Operating leases: Weighted-average remaining lease term (years) 3.8 4.2 Weighted-average discount rate 6.9 % 6.9 % Finance leases: Weighted-average remaining lease term (years) 1.8 1.5 Weighted-average discount rate 8.6 % 8.8 % Maturities of operating leases liabilities as of September 30, 2022, are as follows, in thousands: Remaining period in 2022 $ 202 2023 755 2024 617 2025 534 2026 468 2027 64 Thereafter — Total lease payments 2,640 Less: present value discount (335) Total leases $ 2,305 Maturities of finance lease liabilities as of September 30, 2022, are as follows, in thousands: Remaining period in 2022 $ 30 2023 91 2024 49 2025 4 Thereafter — Total finance lease payments 174 Less: imputed interest (13) Total leases $ 161 Operating lease expenses were $0.2 million and $0.3 million for the three months ended September 30, 2022 and 2021, respectively, and $0.7 million and $0.7 million for the nine months ended September 30, 2022 and 2021, respectively.

DEBT

DEBT	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
DEBT	DEBT The following table presents debt balances: September 30, December 31, (in thousands) 2022 2021 Term loan 10,162 10,070 Term loan issuance costs, net (411) (532) Total long-term debt, net $ 9,751 $ 9,538 Term loan

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company incurred $0.02 million and zero of income tax expense for the nine months ended September 30, 2022, and 2021, respectively. The income taxes for the periods ended September 30, 2022, are primarily attributed to certain state taxes. The Company continues to be in a loss position as of September 30, 2022. The effective income tax rate in each period differed from the federal statutory tax rate of 21% primarily as a result of the ongoing losses. As of September 30, 2022, the Company recorded a full valuation allowance against all of its net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the foreseeable future. On August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022, which, among other things, implements a 15% minimum tax on book income of certain large corporations, a 1% excise tax on net stock repurchases and several tax incentives to promote clean energy. The Company has evaluated the impacts of this legislation to the financial statements but does not expect them to be material.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Legal Following MYOS Rens Technology Inc.’s, or MYOS’s and MedAvail, Inc.’s, or MAI's, announcement of the execution of the Merger Agreement on June 30, 2020, MYOS received separate litigation demands from purported MYOS stockholders on September 16, 2020 and October 20, 2020, respectively seeking certain additional disclosures in the Form S-4 Registration Statement filed with the Securities and Exchange Commission on September 2, 2020, collectively, the Demands. Thereafter, on September 23, 2020, a complaint regarding the transactions contemplated within the Merger Agreement was filed in the Supreme Court of the State of New York, County of New York, captioned Faasse v. MYOS RENS Technology Inc., et. al., Index No.: 654644/2020 (NY Supreme Ct., NY Cnty., September 23, 2020), or the New York Complaint. On October 12, 2020, a second complaint regarding the transactions was filed in the District Court of Nevada, Clark County Nevada, captioned Vigil v. Mannello, et. al., Case No. A-20-822848-C, or the Nevada Complaint, and together with the New York Complaint, the Complaints, and collectively with the Demands, the Litigation. The Demands and the Complaints that comprised the Litigation generally alleged that the directors of MYOS breached their fiduciary duties by entering into the Merger Agreement, and MYOS and MAI disseminated an incomplete and misleading Form S-4 Registration Statement. The New York Complaint also alleged MedAvail aided and abetted such breach of fiduciary duties.

EQUITY, SHARE-BASED COMPENSATIO

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS	EQUITY, SHARE-BASED COMPENSATION AND WARRANTS On June 14, 2022, the Company’s stockholders approved an Amended and Restated Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock, par value $0.001, from 100 million shares to a new total of 300 million shares. The Restated Certificate was effective upon filing the Restated Certificate with the Secretary of State of the State of Delaware on June 15, 2022. Private Placement On March 30, 2022, the Company entered into a Securities Purchase Agreement, or Purchase Agreement, with certain purchasers thereto, or the Investors. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Investors in a private placement, or the Private Placement, up to 47.1 million shares, or the Shares, of the Company’s common stock, and to issue warrants, or the Warrants, to purchase up to 23.5 million shares of common stock, or Warrant Shares. The Shares and the Warrants were sold at two closings as further described below, at a price per share of $1.0625. Each Investor purchasing Shares in the Private Placement was issued a Warrant to purchase that number of Warrant Shares equal to 50% of the number of Shares purchased under the Purchase Agreement by such Investor. The Warrants have a per share exercise price of $1.25 and will be exercisable by the holder at any time on or after the issuance date of the Warrant for a period of five years. If the Warrants were exercised in full immediately after issuance by the Investors, the Company would receive additional gross proceeds of up to $29.4 million. In addition, the Warrant terms provide the Company with a call option to force the Warrant holders to exercise up to two-thirds of the warrant shares subject to each Warrant, with one-third of the Warrant Shares being callable beginning on each of the 12 month and 24 month anniversaries of the Warrant issuance dates, in each case until the expiration of the Warrants, and subject to the satisfaction of certain pricing conditions relating to the trading of the Company’s shares. If the Company were to exercise the contingent call options immediately after issuance, approximately $19.6 million in gross proceeds could be raised. On April 4, 2022, the first closing of the Private Placement occurred, in which 37.6 million shares of common stock for $40.0 million in gross proceeds, before deducting placement agent commissions and other offering expenses, and Warrants exercisable for up to 18.8 million Warrant Shares were issued by the Company. A second and final closing occurred on July 1, 2022, and the Investors purchased an additional 9.4 million shares of common stock for $10.0 million in additional gross proceeds and Warrants exercisable for up to 4.7 million Warrants Shares. Shelf Registration and Sales Agreement On August 12, 2022, the Company filed a shelf registration statement on Form S-3, or the Shelf, with the SEC in relation to the registration and potential future issuance of common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts, units and/or any combination thereof, in the aggregate amount of up to $150,000,000. The Shelf was declared effective on August 26, 2022. The Company also entered into a sales agreement as of August 12, 2022, or Sales Agreement, with Cowen and Company, LLC, or Cowen, as sales agent, providing for the offering, issuance and sale of up to an aggregate $50,000,000 of the Company’s common stock from time to time at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act, including sales made directly on the Nasdaq Capital Market or any other trading market for the Company’s common stock in “at-the-market” offerings, under the Shelf. As of September 30, 2022, the Company has not issued and sold any shares of common stock under the Sales Agreement. Share-based compensation The following table presents the Company's expense related to share-based compensation (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Share-based compensation $ 565 $ 365 $ 1,741 $ 948 The share-based compensation expense for the three and nine months ended September 30, 2022 and inclu ded $0.02 million and $0.1 million , re spectively, from employee stock purchase plan expense. The expense remaining to be recognized for unvested option awards from the 2012, 2018, and 2020 plans and the 2022 inducement plan as of September 30, 2022 was $2.4 million, which is expected to be recognized on a weighted average basis over the next 2.7 years. The expense remaining to be recognized for unvested restricted stock units was $2.2 million, which will be recognized on a weighted average basis over the next 2.3 years. The following table presents the Company's outstanding option awards activity during the nine months ended September 30, 2022 : (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, beginning of period 2,848,903 $ 2.78 $ 1.44 $ 104 Granted 2,758,040 1.35 0.98 — Exercised/released — — — — Expired (117,730) 1.99 1.08 5 Forfeited (952,488) 2.52 1.42 111 Outstanding, end of period 4,536,725 $ 1.93 $ 1.15 8.33 $ — Vested and exercisable, end of the period 1,777,907 2.28 1.16 6.79 — Vested and unvested exercisable, end of the period 1,777,907 2.28 1.16 6.79 — Vested and expected to vest, end of the period 4,309,018 1.94 1.15 8.29 — The following table presents the Company's outstanding restricted stock unit activity during the nine months ended September 30, 2022: (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, beginning of period 802,740 $ — $ 2.78 $ 1,124 Granted 1,601,824 — 1.41 2,252 Exercised/released (46,009) — $ 1.17 6.32 54 Expired — — — — Forfeited (585,973) — 2.05 791 Outstanding, end of period 1,772,582 $ — $ 1.69 4.93 $ 1,376 Vested and exercisable, end of the period — — — — Vested and unvested exercisable, end of the period — — — — Vested and expected to vest, end of the period 1,628,975 — 1.69 4.92 1,264 An aggregate of 2.8 million and 3.4 million shares of common stock was available for grant under the 2020 Plan as of September 30, 2022 and December 31, 2021, respectively. In April 2022, the Company adopted the MedAvail Holdings, Inc. 2022 Inducement Equity Incentive Plan or the Inducement Plan. The Inducement Plan reserved 1,500,000 shares of the Company’s common stock for issuance pursuant to equity awards granted under the Inducement Plan. On April 8, 2022, the Company issued inducement awards to employees that included options to purchase 426,500 shares of Company common stock, and 426,500 restricted stock units. The inducement stock options have an exercise price of $1.96, and 25% of the shares vest on the one year anniversary of the date that employment commenced, and an additional one forty-eighth (1/48th) of the shares vest monthly thereafter. The inducement restricted stock units vest at one-third (1/3rd) of the shares on the first, second and third yearly anniversaries of March 1, 2022. Warrants During the nine months ended September 30, 2022, 18.8 million warrants were issued from the first closing of the Private Placement in April 2022 with a fair value of $7.5 million. 4.7 million warrants were issued from the second closing of the Private Placement in July 2022 with a fair value of $2.3 million. No warrants were exercised during the nine months ended September 30, 2022. There were 24.2 million related party warrants outstanding as of September 30, 2022. The terms for the warrants issued from the Private Placement were as follows: September 30, 2022 Issue Date Reason for issuance Term (years) Exercise Price (USD) April 4, 2022 Private Placement 5 $ 1.25 July 1, 2022 Private Placement 5 $ 1.25

REVENUE AND SEGMENT REPORTING

REVENUE AND SEGMENT REPORTING	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
REVENUE AND SEGMENT REPORTING	REVENUE AND SEGMENT REPORTING Operating segments are the individual operations that the chief operating decision maker, or CODM, who is the Company's chief executive officer, reviews for purposes of assessing performance and making resource allocation decisions. The CODM currently receives the monthly management report which includes information to assess performance. The retail pharmacy services and pharmacy technology operating segments both engage in different business activities from which they earn revenues and incur expenses. The Company has the following two reportable segments: Retail Pharmacy Services Segment Retail Pharmacy Services segment revenue consists of products sold directly to consumers at the point of sale. MedAvail recognizes retail pharmacy revenue, net of taxes and expected returns, at the time it sells merchandise or dispenses prescription drugs to the customer. The Company estimates revenue based on expected reimbursements from third-party payers (e.g., pharmacy benefit managers, insurance companies and governmental agencies) for dispensing prescription drugs. The estimates are based on all available information including historical experience and are updated to actual reimbursement amounts. Pharmacy Technology Segment The Pharmacy Technology Segment consists of sales and subscriptions of MedPlatform systems to customers. These agreements include providing the MedCenter prescription dispensing kiosk, software, and maintenance services. This generally includes either an initial lump sum payment upon installation of the MedCenter with monthly payments for software and services following, or monthly payments for the MedCenter along with monthly payments for software and maintenance services for subscription agreements. The following tables present revenue and costs of products sold and services by segment (in thousands): Retail Pharmacy Services Pharmacy Technology Total Three Months Ended September 30, 2022 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 11,162 $ — $ 11,162 Hardware — — — Subscription — 104 104 Total pharmacy and hardware revenue 11,162 104 11,266 Service revenue: Software — 94 94 Maintenance and support — 48 48 Installation — — — Professional services and other — 53 53 Total service revenue — 195 195 Total revenue 11,162 299 11,461 Cost of products sold and services 10,047 122 10,169 Segment gross profit $ 1,115 $ 177 1,292 Operating expense: Pharmacy operations 4,392 General and administrative 6,087 Selling and marketing 2,126 Research and development 178 Total operating expense 12,783 Operating loss $ (11,491) Retail Pharmacy Services Pharmacy Technology Total Three Months Ended September 30, 2021 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 5,445 $ — $ 5,445 Hardware — 106 106 Subscription — 108 108 Total pharmacy and hardware revenue 5,445 214 5,659 Service revenue: Software — 51 51 Maintenance and support — 44 44 Installation — 11 11 Professional services and other — 27 27 Total service revenue — 133 133 Total revenue 5,445 347 5,792 Cost of products sold and services 5,366 240 5,606 Segment gross profit $ 79 $ 107 186 Operating expense: Pharmacy operations 3,750 General and administrative 5,320 Selling and marketing 1,909 Research and development 232 Total operating expense 11,211 Operating loss $ (11,025) Retail Pharmacy Services Pharmacy Technology Total Nine Months Ended September 30, 2022 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 30,652 $ — $ 30,652 Hardware — 236 236 Subscription — 322 322 Total pharmacy and hardware revenue 30,652 558 31,210 Service revenue: Software — 228 228 Maintenance and support — 127 127 Installation — 77 77 Professional services and other — 117 117 Total service revenue — 549 549 Total revenue 30,652 1,107 31,759 Cost of products sold and services 28,460 588 29,048 Segment gross profit $ 2,192 $ 519 2,711 Operating expense: Pharmacy operations 11,970 General and administrative 18,729 Selling and marketing 6,738 Research and development 952 Total operating expense 38,389 Operating loss $ (35,678) Retail Pharmacy Services Pharmacy Technology Total Nine Months Ended September 30, 2021 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 13,357 $ — $ 13,357 Hardware — 470 470 Subscription — 338 338 Total pharmacy and hardware revenue 13,357 808 14,165 Service revenue: Software — 125 125 Maintenance and support — 115 115 Installation — 39 39 Professional services and other — 405 405 Total service revenue — 684 684 Total revenue 13,357 1,492 14,849 Cost of products sold and services 13,130 1,040 14,170 Segment gross profit $ 227 $ 452 679 Operating expense: Pharmacy operations 9,428 General and administrative 16,733 Selling and marketing 5,056 Research and development 601 Total operating expense 31,818 Operating loss $ (31,139) The following table presents assets and liabilities by segment (in thousands): Retail Pharmacy Services Pharmacy Technology Corporate Total September 30, 2022 Assets $ 15,939 $ 7,953 $ 25,959 $ 49,851 Liabilities $ 5,841 $ 2,689 $ 10,015 $ 18,545 December 31, 2021 Assets $ 13,641 $ 5,222 $ 19,280 $ 38,143 Liabilities $ 5,618 $ 3,567 $ 9,885 $ 19,070 The following table presents long-lived assets, which include property, plant, and equipment and right-of-use-assets by geographic region, based on the physical location of the assets (in thousands): September 30, December 31, 2022 2021 Long-lived assets: United States $ 8,286 $ 7,675 Canada 354 555 Total long-lived assets $ 8,640 $ 8,230

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS Nasdaq Capital Market Listing Qualifications The Company received a deficiency letter from the Listing Qualifications Department of the Nasdaq Capital Market (“Nasdaq”) on October 31, 2022 notifying the Company that for the last 30 consecutive business days the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion in Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter will not result in the immediate delisting of the Company’s common stock from Nasdaq. The Company has an initial period of 180 calendar days, or until May 1, 2023, to regain compliance with the Bid Price Rule. If the Company is not in compliance with the Bid Price Rule within the first 180 calendar days, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards required by Nasdaq, except for the minimum bid price requirement.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying unaudited condensed consolidated financial statements as of September 30, 2022 and for the three and nine months ended September 30, 2022 and 2021 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information and in accordance with the rules of the Securities and Exchange Commission ("SEC") applicable to interim reports of companies filing as a smaller reporting company. Accordingly, the unaudited interim condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The condensed consolidated balance sheet as of December 31, 2021 was derived from the Company's audited consolidated financial statements but does not include all disclosures required by GAAP for audited financial statements. In the opinion of the Company's management, the interim information includes all adjustments, which include normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, 2021 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission, or SEC on March 29, 2022, or the 2021 Form 10-K. The preparation of financial statements in accordance with US GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. Estimates are used in accounting for,
Principles of consolidation	Principles of consolidation The unaudited condensed consolidated financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated.
Recent Accounting Pronouncements and Recently Adopted Accounting Standards	RECENT ACCOUNTING PRONOUNCEMENTS Measurement of Credit Losses on Financial Statements In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)”- Measurement of Credit Losses on Financial Instruments”, (“ASU 2016-13”), supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, (“ASU 2018-19”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, all other public business entities and private companies, with early adoption permitted. ASU No. 2016-13 will be effective beginning in the first quarter of the Company's fiscal year 2023. The Company is currently evaluating the impact that this new guidance will have on its consolidated financial statements and related disclosures. In June 2022, the FASB issued ASU No. 2022-03, “Fair Value Measurement (Topic 820)”- Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, (“ASU 2022-03”). The amendments in this update clarify the guidance in Topic 820. ASU 2022-03 becomes effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. ASU No. 2022-03 will be effective beginning in the first quarter of the Company's fiscal year 2024. The Company has not yet completed its evaluation of the impact of this new guidance on its consolidated financial statements. Recently Adopted Accounting Standards There was no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s condensed consolidated financial statements through the reporting date.

BASIS OF PRESENTATION (Tables)

BASIS OF PRESENTATION (Tables)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	The effect of the reclassifications within the condensed consolidated statement of operations and comprehensive loss for 2021 are as follows (in thousands): Three Months Ended September 30, 2021 Current presentation As previously reported Change Pharmacy operations $ 3,750 $ 2,395 $ 1,355 General and administrative 5,320 6,805 (1,485) Selling and marketing 1,909 1,779 130 $ 10,979 $ 10,979 $ — Nine Months Ended September 30, 2021 Current presentation As previously reported Change Pharmacy operations $ 9,428 $ 6,619 $ 2,809 General and administrative 16,733 19,941 (3,208) Selling and marketing 5,056 4,657 399 $ 31,217 $ 31,217 $ —

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of Warrants Included in Earnings per Share	The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price, during the period from the date of issuance to the exercise date. After these warrants were exercised the related issued and outstanding common shares are included in weighted average shares outstanding: Shares Issuance Date Exercise Date 118,228 May 9, 2018 May 10, 2021 309,698 February 11, 2020 May 10, 2021 84,911 June 29, 2020 May 10, 2021 39,208 November 18, 2020 May 10, 2021 19,310 November 18, 2020 Outstanding

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	Assets and liabilities measured at fair value on a recurring basis were as follows: Fair Value Hierarchy (in thousands) September 30, 2022 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 27,196 $ 27,196 $ — $ — Restricted cash 676 676 — — Total assets $ 27,872 $ 27,872 $ — $ — Fair Value Hierarchy (in thousands) December 31, 2021 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 19,689 $ 19,689 $ — $ — Restricted cash 400 400 — — Total assets $ 20,089 $ 20,089 $ — $ —

BALANCE SHEET AND OTHER INFOR_2

BALANCE SHEET AND OTHER INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventory	The following table presents detail of inventory balances: September 30, December 31, (in thousands) 2022 2021 Inventory: MedCenter hardware $ 2,464 $ 1,201 Pharmaceuticals 3,275 2,150 Spare parts 662 565 Total inventory $ 6,401 $ 3,916
Schedule of Prepaid Expenses and Other Current Assets	The following table presents prepaid expenses and other current assets balances: September 30, December 31, (in thousands) 2022 2021 Prepaid expenses and other current assets: Prepaid MedCenter inventory $ 2,204 $ 1,050 Prepaid insurance 292 509 Other 367 632 Total prepaid expenses and other current assets $ 2,863 $ 2,191
Schedule of Property, Plant and Equipment, Net and Useful Lives	The following table presents property, plant and equipment balances: Estimated useful lives September 30, December 31, (in thousands) 2022 2021 Property, plant and equipment: MedCenter equipment 8 years $ 7,525 $ 5,875 IT equipment 1 - 3 years 2,390 2,361 Leasehold improvements lesser of useful life or term of lease 980 880 General plant and equipment 5 - 8 years 619 603 Office furniture and equipment 5 - 8 years 538 394 Vehicles 5 years 54 54 Construction-in-process 481 1,021 Total historical cost 12,587 11,188 Accumulated depreciation (6,217) (5,496) Total property, plant and equipment, net $ 6,370 $ 5,692
Schedule of Finite-Lived Intangible Assets, Net	The following table presents intangible asset balances: September 30, December 31, (in thousands) 2022 2021 Gross intangible assets: Intellectual property $ 3,857 $ 3,857 Software 5,321 4,475 Website and mobile application 583 583 Total intangible assets 9,761 8,915 Accumulated amortization: Intellectual property (3,857) (3,857) Software (3,741) (2,175) Website and mobile application (583) (583) Total accumulated amortization (8,181) (6,615) Total intangible assets, net $ 1,580 $ 2,300
Schedule of Lease Assets and Liabilities	Balance sheet amounts for lease assets and leases liabilities are as follows: September 30, December 31, (in thousands) 2022 2021 Assets: Operating $ 2,110 $ 2,376 Finance 160 162 Total assets $ 2,270 $ 2,538 Liabilities: Operating: Current $ 632 $ 599 Long-term 1,673 1,947 Finance: Current 96 83 Long-term 65 80 Total liabilities $ 2,466 $ 2,709 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows: September 30, December 31, (in thousands) 2022 2021 Operating leases: Weighted-average remaining lease term (years) 3.8 4.2 Weighted-average discount rate 6.9 % 6.9 % Finance leases: Weighted-average remaining lease term (years) 1.8 1.5 Weighted-average discount rate 8.6 % 8.8 %
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating leases liabilities as of September 30, 2022, are as follows, in thousands: Remaining period in 2022 $ 202 2023 755 2024 617 2025 534 2026 468 2027 64 Thereafter — Total lease payments 2,640 Less: present value discount (335) Total leases $ 2,305
Schedule of Maturities of Finance Lease Liabilities	Maturities of finance lease liabilities as of September 30, 2022, are as follows, in thousands: Remaining period in 2022 $ 30 2023 91 2024 49 2025 4 Thereafter — Total finance lease payments 174 Less: imputed interest (13) Total leases $ 161

DEBT (Tables)

DEBT (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Debt	The following table presents debt balances: September 30, December 31, (in thousands) 2022 2021 Term loan 10,162 10,070 Term loan issuance costs, net (411) (532) Total long-term debt, net $ 9,751 $ 9,538

EQUITY, SHARE-BASED COMPENSAT_2

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Schedule of MedAvail Share-based Compensation Expense	The following table presents the Company's expense related to share-based compensation (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Share-based compensation $ 565 $ 365 $ 1,741 $ 948
Schedule of Outstanding Option Awards Activity	The following table presents the Company's outstanding option awards activity during the nine months ended September 30, 2022 : (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, beginning of period 2,848,903 $ 2.78 $ 1.44 $ 104 Granted 2,758,040 1.35 0.98 — Exercised/released — — — — Expired (117,730) 1.99 1.08 5 Forfeited (952,488) 2.52 1.42 111 Outstanding, end of period 4,536,725 $ 1.93 $ 1.15 8.33 $ — Vested and exercisable, end of the period 1,777,907 2.28 1.16 6.79 — Vested and unvested exercisable, end of the period 1,777,907 2.28 1.16 6.79 — Vested and expected to vest, end of the period 4,309,018 1.94 1.15 8.29 —
Schedule of Outstanding RSU Awards Activity	The following table presents the Company's outstanding restricted stock unit activity during the nine months ended September 30, 2022: (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, beginning of period 802,740 $ — $ 2.78 $ 1,124 Granted 1,601,824 — 1.41 2,252 Exercised/released (46,009) — $ 1.17 6.32 54 Expired — — — — Forfeited (585,973) — 2.05 791 Outstanding, end of period 1,772,582 $ — $ 1.69 4.93 $ 1,376 Vested and exercisable, end of the period — — — — Vested and unvested exercisable, end of the period — — — — Vested and expected to vest, end of the period 1,628,975 — 1.69 4.92 1,264
Schedule of Warrants Issued	The terms for the warrants issued from the Private Placement were as follows: September 30, 2022 Issue Date Reason for issuance Term (years) Exercise Price (USD) April 4, 2022 Private Placement 5 $ 1.25 July 1, 2022 Private Placement 5 $ 1.25

REVENUE AND SEGMENT REPORTING (

REVENUE AND SEGMENT REPORTING (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Schedule of Revenue and Costs of Sales by Segment	The following tables present revenue and costs of products sold and services by segment (in thousands): Retail Pharmacy Services Pharmacy Technology Total Three Months Ended September 30, 2022 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 11,162 $ — $ 11,162 Hardware — — — Subscription — 104 104 Total pharmacy and hardware revenue 11,162 104 11,266 Service revenue: Software — 94 94 Maintenance and support — 48 48 Installation — — — Professional services and other — 53 53 Total service revenue — 195 195 Total revenue 11,162 299 11,461 Cost of products sold and services 10,047 122 10,169 Segment gross profit $ 1,115 $ 177 1,292 Operating expense: Pharmacy operations 4,392 General and administrative 6,087 Selling and marketing 2,126 Research and development 178 Total operating expense 12,783 Operating loss $ (11,491) Retail Pharmacy Services Pharmacy Technology Total Three Months Ended September 30, 2021 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 5,445 $ — $ 5,445 Hardware — 106 106 Subscription — 108 108 Total pharmacy and hardware revenue 5,445 214 5,659 Service revenue: Software — 51 51 Maintenance and support — 44 44 Installation — 11 11 Professional services and other — 27 27 Total service revenue — 133 133 Total revenue 5,445 347 5,792 Cost of products sold and services 5,366 240 5,606 Segment gross profit $ 79 $ 107 186 Operating expense: Pharmacy operations 3,750 General and administrative 5,320 Selling and marketing 1,909 Research and development 232 Total operating expense 11,211 Operating loss $ (11,025) Retail Pharmacy Services Pharmacy Technology Total Nine Months Ended September 30, 2022 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 30,652 $ — $ 30,652 Hardware — 236 236 Subscription — 322 322 Total pharmacy and hardware revenue 30,652 558 31,210 Service revenue: Software — 228 228 Maintenance and support — 127 127 Installation — 77 77 Professional services and other — 117 117 Total service revenue — 549 549 Total revenue 30,652 1,107 31,759 Cost of products sold and services 28,460 588 29,048 Segment gross profit $ 2,192 $ 519 2,711 Operating expense: Pharmacy operations 11,970 General and administrative 18,729 Selling and marketing 6,738 Research and development 952 Total operating expense 38,389 Operating loss $ (35,678) Retail Pharmacy Services Pharmacy Technology Total Nine Months Ended September 30, 2021 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 13,357 $ — $ 13,357 Hardware — 470 470 Subscription — 338 338 Total pharmacy and hardware revenue 13,357 808 14,165 Service revenue: Software — 125 125 Maintenance and support — 115 115 Installation — 39 39 Professional services and other — 405 405 Total service revenue — 684 684 Total revenue 13,357 1,492 14,849 Cost of products sold and services 13,130 1,040 14,170 Segment gross profit $ 227 $ 452 679 Operating expense: Pharmacy operations 9,428 General and administrative 16,733 Selling and marketing 5,056 Research and development 601 Total operating expense 31,818 Operating loss $ (31,139)
Schedule of Assets and Liabilities by Segment	The following table presents assets and liabilities by segment (in thousands): Retail Pharmacy Services Pharmacy Technology Corporate Total September 30, 2022 Assets $ 15,939 $ 7,953 $ 25,959 $ 49,851 Liabilities $ 5,841 $ 2,689 $ 10,015 $ 18,545 December 31, 2021 Assets $ 13,641 $ 5,222 $ 19,280 $ 38,143 Liabilities $ 5,618 $ 3,567 $ 9,885 $ 19,070 The following table presents long-lived assets, which include property, plant, and equipment and right-of-use-assets by geographic region, based on the physical location of the assets (in thousands): September 30, December 31, 2022 2021 Long-lived assets: United States $ 8,286 $ 7,675 Canada 354 555 Total long-lived assets $ 8,640 $ 8,230

GOING CONCERN (Details)

GOING CONCERN (Details) - USD ($) $ in Thousands			1 Months Ended			9 Months Ended		12 Months Ended
	Jul. 01, 2022	Apr. 04, 2022	Jul. 31, 2022	Apr. 30, 2022	Mar. 31, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Debt Instrument [Line Items]
Operating cash flows						$ (37,283)	$ (28,174)
Cash and cash equivalents						27,196		$ 19,689
Accumulated deficit						(228,636)		(192,090)
Stock issuance costs	$ 3,000
Proceeds from debt						$ 0	$ 10,000
Term loan | Secured Debt
Debt Instrument [Line Items]
Proceeds from debt								$ 10,000
Minimum
Debt Instrument [Line Items]
Warrants, callable term				12 months	12 months
Maximum
Debt Instrument [Line Items]
Warrants, callable term				24 months	24 months
Private Placement
Debt Instrument [Line Items]
Gross proceeds from private placement	$ 10,000	$ 40,000	$ 10,000	$ 40,000

BASIS OF PRESENTATION - Reclass

BASIS OF PRESENTATION - Reclassifications (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Pharmacy operations	$ 4,392	$ 3,750	$ 11,970	$ 9,428
General and administrative	6,087	5,320	18,729	16,733
Selling and marketing	$ 2,126	1,909	$ 6,738	5,056
Total		10,979		31,217
As previously reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Pharmacy operations		2,395		6,619
General and administrative		6,805		19,941
Selling and marketing		1,779		4,657
Total		10,979		31,217
Change
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Pharmacy operations		1,355		2,809
General and administrative		(1,485)		(3,208)
Selling and marketing		130		399
Total		$ 0		$ 0

EARNINGS (LOSS) PER SHARE - War

EARNINGS (LOSS) PER SHARE - Warrants Included in Earnings per Share (Details)	9 Months Ended
	Sep. 30, 2022 shares
Warrants Issued May 9, 2018
Class of Warrant or Right [Line Items]
Warrants (in shares)	118,228
Warrants Issued February 11, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)	309,698
Warrants Issued June 29, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)	84,911
Warrants Issued November 18, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)	39,208
Warrants Issued November 18, 2020, Outstanding
Class of Warrant or Right [Line Items]
Warrants (in shares)	19,310

EARNINGS (LOSS) PER SHARE - Nar

EARNINGS (LOSS) PER SHARE - Narrative (Details) - shares shares in Millions	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive option awards excluded from earnings per share calculation (in shares)	4.5	2.9
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive option awards excluded from earnings per share calculation (in shares)	24.3		0.7

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 27,196	$ 19,689
Restricted cash	676	400
Total assets	27,872	20,089
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	27,196	19,689
Restricted cash	676	400
Total assets	27,872	20,089
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	0	0
Total assets	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	0	0
Total assets	$ 0	$ 0

BALANCE SHEET AND OTHER INFOR_3

BALANCE SHEET AND OTHER INFORMATION - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Feb. 28, 2022	Dec. 31, 2021
Inventory [Line Items]
Restricted cash	$ 676,000		$ 676,000			$ 400,000
Letters of credit outstanding, amount					$ 300,000
Depreciation of property, plant, and equipment	300,000	$ 300,000	891,000	$ 928,000
Depreciation included in cost of sales	30,000	50,000	100,000	100,000
Increase of intangible assets during the period	0	700,000	900,000	1,900,000
Amortization of intangible assets	1,300,000	100,000	1,600,000	200,000
Operating lease, expense	200,000	300,000	700,000	700,000
Pharmacy
Inventory [Line Items]
Inventory recognized as cost of sales	9,300,000	5,000,000	26,400,000	12,200,000
MedCenter
Inventory [Line Items]
Inventory recognized as cost of sales	10,000	$ 100,000	200,000	$ 500,000
Guarantee for Purchasing Cards
Inventory [Line Items]
Cash released from restriction			100,000
Letter of Credit Security
Inventory [Line Items]
Restricted cash	$ 700,000		$ 700,000

BALANCE SHEET AND OTHER INFOR_4

BALANCE SHEET AND OTHER INFORMATION - Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
MedCenter hardware	$ 2,464	$ 1,201
Pharmaceuticals	3,275	2,150
Spare parts	662	565
Total inventory	$ 6,401	$ 3,916

BALANCE SHEET AND OTHER INFOR_5

BALANCE SHEET AND OTHER INFORMATION - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Prepaid expenses and other current assets:
Prepaid MedCenter inventory	$ 2,204	$ 1,050
Prepaid insurance	292	509
Other	367	632
Total prepaid expenses and other current assets	$ 2,863	$ 2,191

BALANCE SHEET AND OTHER INFOR_6

BALANCE SHEET AND OTHER INFORMATION - Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Historical cost	$ 12,587	$ 11,188
Accumulated depreciation	(6,217)	(5,496)
Total property, plant and equipment, net	$ 6,370	5,692
MedCenter equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years
Historical cost	$ 7,525	5,875
IT equipment
Property, Plant and Equipment [Line Items]
Historical cost	$ 2,390	2,361
IT equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	1 year
IT equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Historical cost	$ 980	880
General plant and equipment
Property, Plant and Equipment [Line Items]
Historical cost	$ 619	603
General plant and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
General plant and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years
Office furniture and equipment
Property, Plant and Equipment [Line Items]
Historical cost	$ 538	394
Office furniture and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Office furniture and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years
Vehicles
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Historical cost	$ 54	54
Construction-in-process
Property, Plant and Equipment [Line Items]
Historical cost	$ 481	$ 1,021

BALANCE SHEET AND OTHER INFOR_7

BALANCE SHEET AND OTHER INFORMATION - Intangible Assets, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	$ 9,761	$ 8,915
Accumulated amortization	(8,181)	(6,615)
Total intangible assets, net	1,580	2,300
Intellectual property
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	3,857	3,857
Accumulated amortization	(3,857)	(3,857)
Software
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	5,321	4,475
Accumulated amortization	(3,741)	(2,175)
Website and mobile application
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	583	583
Accumulated amortization	$ (583)	$ (583)

BALANCE SHEET AND OTHER INFOR_8

BALANCE SHEET AND OTHER INFORMATION - Leases, Balance Sheet Information (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Assets
Operating	$ 2,110	$ 2,376
Finance	160	162
Total assets	2,270	2,538
Operating:
Current	632	599
Long-term	1,673	1,947
Finance:
Current	96	83
Long-term	65	80
Total liabilities	$ 2,466	$ 2,709

BALANCE SHEET AND OTHER INFOR_9

BALANCE SHEET AND OTHER INFORMATION - Additional Lease Information (Details)	Sep. 30, 2022	Dec. 31, 2021
Operating leases:
Weighted-average remaining lease term (years)	3 years 9 months 18 days	4 years 2 months 12 days
Weighted-average discount rate	6.90%	6.90%
Finance leases:
Weighted-average remaining lease term (years)	1 year 9 months 18 days	1 year 6 months
Weighted-average discount rate	8.60%	8.80%

BALANCE SHEET AND OTHER INFO_10

BALANCE SHEET AND OTHER INFORMATION - Leases, Operating Lease Liability Maturity (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Remaining period in 2022	$ 202
2023	755
2024	617
2025	534
2026	468
2027	64
Thereafter	0
Total lease payments	2,640
Less: present value discount	(335)
Total leases	$ 2,305

BALANCE SHEET AND OTHER INFO_11

BALANCE SHEET AND OTHER INFORMATION - Leases, Finance Lease Liability Maturity (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Remaining period in 2022	$ 30
2023	91
2024	49
2025	4
Thereafter	0
Total finance lease payments	174
Less: imputed interest	(13)
Total leases	$ 161

DEBT - Schedule of Debt (Detail

DEBT - Schedule of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Long-term debt, net	$ 9,751	$ 9,538
Term loan | Secured Debt
Debt Instrument [Line Items]
Term loan	10,162	10,070
Term loan issuance costs, net	$ (411)	$ (532)

DEBT - Narrative (Details)

DEBT - Narrative (Details) - Term loan - Secured Debt	9 Months Ended
	Sep. 30, 2022
Debt Instrument [Line Items]
Debt instrument, interest rate floor	7.25%
Interest rate at end of period	10.25%
Prime Rate
Debt Instrument [Line Items]
Variable interest rate spread	4%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 2	$ 24	$ 2

EQUITY, SHARE-BASED COMPENSAT_3

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Equity, Narrative (Details) - $ / shares	Sep. 30, 2022	Jun. 14, 2022	Jun. 13, 2022	Dec. 31, 2021
Equity [Abstract]
Common shares, par value (in USD per share)	$ 0.001	$ 0.001		$ 0.001
Common shares, authorized (in shares)	300,000,000	300,000,000	100,000,000	300,000,000

EQUITY, SHARE-BASED COMPENSAT_4

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Private Placement and Shelf Registration and Sales Agreement Narrative (Details) $ / shares in Units, shares in Millions, $ in Millions				1 Months Ended
	Aug. 12, 2022 USD ($)	Jul. 01, 2022 USD ($) shares	Apr. 04, 2022 USD ($) shares	Jul. 31, 2022 USD ($)	Apr. 30, 2022 USD ($)	Mar. 31, 2022	Mar. 30, 2022 USD ($) closing $ / shares shares
Subsidiary, Sale of Stock [Line Items]
Sale of debt and equity securities, authorized amount	$ 150
Sales agreement, offering, issuance, and sale of common stock, authorized amount	$ 50
Minimum
Subsidiary, Sale of Stock [Line Items]
Warrants, callable term					12 months	12 months
Maximum
Subsidiary, Sale of Stock [Line Items]
Warrants, callable term					24 months	24 months
Warrant Shares
Subsidiary, Sale of Stock [Line Items]
Exercise price of warrants issued (in USD per share) | $ / shares							$ 1.25
Term of warrants (in years)							5 years
Proceeds to be received if warrants are exercised in full							$ 29.4
Percentage of warrants callable							66.67%
Exercise the contingent call options, additional equity							$ 19.6
Warrant Shares | Warrants Callable at 12 Months
Subsidiary, Sale of Stock [Line Items]
Percentage of warrants callable							33.33%
Warrant Shares | Warrants Callable at 24 Months
Subsidiary, Sale of Stock [Line Items]
Percentage of warrants callable							33.33%
Private Placement
Subsidiary, Sale of Stock [Line Items]
Number of shares authorized to be sold (in shares) | shares							47.1
Number of shares called by warrants (in shares) | shares							23.5
Number of closings | closing							2
Sale of stock (in USD per share) | $ / shares							$ 1.0625
Warrants issued as a percentage of shares purchased							50%
Number of shares sold or expected to be sold (in shares) | shares		9.4	37.6
Gross proceeds from private placement		$ 10	$ 40	$ 10	$ 40
Number of warrants issued (in shares) | shares		4.7	18.8

EQUITY, SHARE-BASED COMPENSAT_5

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Equity [Abstract]
Share-based compensation expense	$ 565	$ 365	$ 1,741	$ 948

EQUITY, SHARE-BASED COMPENSAT_6

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation, Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	9 Months Ended
	Apr. 08, 2022	Sep. 30, 2022	Sep. 30, 2022	Apr. 30, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense remaining to be recognized		$ 2,400	$ 2,400
Weighted average recognition period (in years)			2 years 8 months 12 days
Aggregate shares on common stock available for grant (in shares)		2,800,000	2,800,000		3,400,000
Granted (in shares)	426,500		2,758,040
Exercise price (in USD per share)	$ 1.96		$ 1.35
2022 Inducement Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance (in shares)				1,500,000
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		$ 20	$ 100
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense remaining to be recognized		$ 2,200	$ 2,200
Weighted average recognition period (in years)			2 years 3 months 18 days
Granted (in shares)	426,500
Restricted Stock Units (RSUs) | 2022 Inducement Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vesting rights	33.33%
Option | Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vesting rights	25%
Option | Share-based Payment Arrangement, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vesting rights	2.08%

EQUITY, SHARE-BASED COMPENSAT_7

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended
	Apr. 08, 2022	Sep. 30, 2022
Number of Awards
Outstanding awards at beginning of period (in shares)		2,848,903
Granted (in shares)	426,500	2,758,040
Exercised/released (in shares)		0
Expired (in shares)		(117,730)
Forfeited (in shares)		(952,488)
Outstanding awards at end of period (in shares)		4,536,725
Awards vested and exercisable (in shares)		1,777,907
Awards vested and unvested exercisable (in shares)		1,777,907
Awards vested and expected to vest (in shares)		4,309,018
Weighted Average Exercise Price
Weighted average exercise price of awards outstanding at beginning of period (in USD per share)		$ 2.78
Weighted average exercise price of awards granted (in USD per share)	$ 1.96	1.35
Weighted average exercise price of awards exercised/released (in USD per share)		0
Weighted average exercise price of awards expired (in USD per share)		1.99
Weighted average exercise price of awards forfeited (in USD per share)		2.52
Weighted average exercise price of awards outstanding at end of period (in USD per share)		1.93
Weighted average exercise price of awards vested and exercisable (in USD per share)		2.28
Weighted average exercise price of awards vested and unvested exercisable (in USD per share)		2.28
Weighted average exercise price of awards vested and expected to vest (in USD per share)		1.94
Weighted Average Fair Value
Weighted average fair value of awards outstanding at beginning of period (in USD per share)		1.44
Grant date fair value of options granted (in USD per share)		0.98
Weighted average fair value of awards exercised/released (in USD per share)		0
Weighted average fair value of awards expired (in USD per share)		1.08
Weighted average fair value of awards forfeited (in USD per share)		1.42
Weighted average fair value of awards outstanding at end of period (in USD per share)		1.15
Weighted average fair value of awards vested and exercisable (in USD per share)		1.16
Weighted average fair value of awards vested and unvested exercisable (in USD per share)		1.16
Weighted average fair value of awards vested and expected to vest (in USD per share)		$ 1.15
Weighted Average Remaining Contractual Life (Years)
Outstanding, end of period		8 years 3 months 29 days
Vested and exercisable, end of the period		6 years 9 months 14 days
Vested and unvested exercisable, end of the period		6 years 9 months 14 days
Vested and expected to vest, end of the period		8 years 3 months 14 days
Aggregate Intrinsic Value
Aggregate intrinsic value of awards outstanding at beginning of period		$ 104
Aggregate intrinsic value of awards granted		0
Aggregate intrinsic value of awards exercised/released		0
Aggregate intrinsic value of awards expired		5
Aggregate intrinsic value of awards forfeited		111
Aggregate intrinsic value of awards outstanding at end of period		0
Aggregate intrinsic value of awards vested and exercisable		0
Aggregate intrinsic value of awards vested and unvested exercisable		0
Aggregate intrinsic value of awards vested and expected to vest		$ 0

EQUITY, SHARE-BASED COMPENSAT_8

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - RSU Activity (Details) - Restricted Stock Units (RSUs) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Number of Awards
Outstanding awards at beginning of period (in shares) | shares	802,740
Granted (in shares) | shares	1,601,824
Exercised/Released (in shares) | shares	(46,009)
Expired (in shares) | shares	0
Forfeited (in shares) | shares	(585,973)
Outstanding awards at end of period (in shares) | shares	1,772,582
Vested and exercisable, end of the period (in shares) | shares	0
Vested and unvested exercisable, end of the period (in shares) | shares	0
Vested and expected to vest, end of the period (in shares) | shares	1,628,975
Weighted Average Share Price on Date of Exercise
Weighted average share price on date of exercise (in USD per share)	$ 1.17
Weighted Average Fair Value
Weighted average fair value of awards outstanding at beginning of period (in USD per share)	2.78
Weighted average grant date fair value of options granted (in USD per share)	1.41
Weighted average fair value of awards exercised/released (in USD per share)	6.32
Weighted average fair value of awards expired (in USD per share)	0
Weighted average fair value of awards cancelled/forfeited (in USD per share)	2.05
Weighted average fair value of awards outstanding at end of period (in USD per share)	1.69
Weighted average fair value of awards vested and exercisable (in USD per share)	0
Weighted average fair value of awards vested and unvested exercisable (in USD per share)	0
Weighted average fair value of awards vested and expected to vest (in USD per share)	$ 1.69
Weighted Average Remaining Contractual Life (Years)
Weighted average remaining contractual life	4 years 11 months 4 days
Vested and expected to vest, end of the period	4 years 11 months 1 day
Aggregate Intrinsic Value
Aggregate intrinsic value of awards outstanding at beginning of period | $	$ 1,124
Aggregate intrinsic value of awards granted | $	2,252
Aggregate intrinsic value of awards exercised/released | $	54
Aggregate intrinsic value of awards expired | $	0
Aggregate intrinsic value of awards forfeited | $	791
Aggregate intrinsic value of awards outstanding at end of period | $	1,376
Aggregate intrinsic value of awards vested and exercisable | $	0
Aggregate intrinsic value of awards vested and unvested exercisable | $	0
Aggregate intrinsic value of awards vested and expected to vest | $	$ 1,264

EQUITY, SHARE-BASED COMPENSAT_9

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Warrants, Narrative (Details) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($) shares
Class of Warrant or Right [Line Items]
Exercise of warrants (in shares)	0
Investors
Class of Warrant or Right [Line Items]
Warrants (in shares)	24,200,000
Warrants Issued April 04, 2022, Exercise Price
Class of Warrant or Right [Line Items]
Warrants issued during the period (in shares)	18,800,000
Fair value of warrants | $	$ 7.5
Warrants Issued July 01, 2022, Exercise Price
Class of Warrant or Right [Line Items]
Warrants issued during the period (in shares)	4,700,000
Fair value of warrants | $	$ 2.3

EQUITY, SHARE-BASED COMPENSA_10

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Schedule of Warrants Issued (Details)	Sep. 30, 2022 $ / shares
Warrants Issued April 04, 2022, Exercise Price
Class of Warrant or Right [Line Items]
Term of warrants (in years)	5 years
Exercise price of warrants issued (in USD per share)	$ 1.25
Warrants Issued July 01, 2022, Exercise Price
Class of Warrant or Right [Line Items]
Term of warrants (in years)	5 years
Exercise price of warrants issued (in USD per share)	$ 1.25

REVENUE AND SEGMENT REPORTING -

REVENUE AND SEGMENT REPORTING - Narrative (Details)	9 Months Ended
	Sep. 30, 2022 segment
Segment Reporting [Abstract]
Number of reportable segments	2

REVENUE AND SEGMENT REPORTING_2

REVENUE AND SEGMENT REPORTING - Schedule of Revenue and Cost of Sales (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	$ 11,461	$ 5,792	$ 31,759	$ 14,849
Total cost of products sold and services	10,169	5,606	29,048	14,170
Operating expense:	1,292	186	2,711	679
Operating expense:
Pharmacy operations	4,392	3,750	11,970	9,428
General and administrative	6,087	5,320	18,729	16,733
Selling and marketing	2,126	1,909	6,738	5,056
Research and development	178	232	952	601
Total operating expense	12,783	11,211	38,389	31,818
Operating loss	(11,491)	(11,025)	(35,678)	(31,139)
Total pharmacy and hardware revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	11,266	5,659	31,210	14,165
Total cost of products sold and services	10,113	5,539	28,827	13,744
Retail pharmacy revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	11,162	5,445	30,652	13,357
Hardware
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	106	236	470
Subscription
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	104	108	322	338
Total service revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	195	133	549	684
Total cost of products sold and services	56	67	221	426
Software
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	94	51	228	125
Maintenance and support
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	48	44	127	115
Installation
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	11	77	39
Professional services and other
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	53	27	117	405
Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	11,162	5,445	30,652	13,357
Total cost of products sold and services	10,047	5,366	28,460	13,130
Operating expense:	1,115	79	2,192	227
Retail Pharmacy Services | Total pharmacy and hardware revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	11,162	5,445	30,652	13,357
Retail Pharmacy Services | Retail pharmacy revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	11,162	5,445	30,652	13,357
Retail Pharmacy Services | Hardware
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0	0	0
Retail Pharmacy Services | Subscription
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0	0	0
Retail Pharmacy Services | Total service revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0	0	0
Retail Pharmacy Services | Software
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0	0	0
Retail Pharmacy Services | Maintenance and support
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0	0	0
Retail Pharmacy Services | Installation
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0	0	0
Retail Pharmacy Services | Professional services and other
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0	0	0
Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	299	347	1,107	1,492
Total cost of products sold and services	122	240	588	1,040
Operating expense:	177	107	519	452
Pharmacy Technology | Total pharmacy and hardware revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	104	214	558	808
Pharmacy Technology | Retail pharmacy revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0	0	0
Pharmacy Technology | Hardware
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	106	236	470
Pharmacy Technology | Subscription
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	104	108	322	338
Pharmacy Technology | Total service revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	195	133	549	684
Pharmacy Technology | Software
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	94	51	228	125
Pharmacy Technology | Maintenance and support
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	48	44	127	115
Pharmacy Technology | Installation
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	11	77	39
Pharmacy Technology | Professional services and other
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	$ 53	$ 27	$ 117	$ 405

REVENUE AND SEGMENT REPORTING_3

REVENUE AND SEGMENT REPORTING - Schedule of Assets and Liabilities by Segment (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$ 49,851	$ 38,143
Liabilities	18,545	19,070
Operating Segments | Retail Pharmacy Services
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	15,939	13,641
Liabilities	5,841	5,618
Operating Segments | Pharmacy Technology
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	7,953	5,222
Liabilities	2,689	3,567
Corporate
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	25,959	19,280
Liabilities	$ 10,015	$ 9,885

REVENUE AND SEGMENT REPORTING_4

REVENUE AND SEGMENT REPORTING - Long-Lived Assets by Geographic Area (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Segment Reporting, Asset Reconciling Item [Line Items]
Total long-lived assets	$ 8,640	$ 8,230
United States
Segment Reporting, Asset Reconciling Item [Line Items]
Total long-lived assets	8,286	7,675
Canada
Segment Reporting, Asset Reconciling Item [Line Items]
Total long-lived assets	$ 354	$ 555